Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- IOC - Artigos de Periódicos [12973]
Metadata
Show full item record
MPLA AND ADDAVAX® ADJUVANTS FAIL TO PROMOTE INTRAMUSCULAR LAAG VACCINE PROTECTIVENESS AGAINST EXPERIMENTAL CUTANEOUS LEISHMANIASIS
Vacina LaAg
Adjuvantes
MPLA
AddaVax®
Intramuscular
Imunização
C57BL/6
LaAg vaccine
Adjuvants
MPLA
AddaVax®
Intramuscular
Immunization
C57BL/6
Author
Affilliation
Abstract
There is so far no vaccine approved for human leishmaniasis, mainly because of the lack of
appropriate adjuvants. This study aimed to evaluate in mice the capacity of a mixture of monophosphoryl
lipid A (MPLA) and AddaVax® adjuvants in enhancing the efficacy of a Leishvacin®-like
vaccine comprised of Leishmania amazonensis whole antigens (LaAg). For that, mice were immunized
with LaAg plus MPLA/AddaVax® by the intramuscular route (i.m.) prior to challenge with 2 105
and 2 106 living parasites. Immunization with LaAg alone reduced the lesion growth of the
2 105-challenged mice only in the peak of infection, but that was not accompanied by reduced parasite
load, and thus not considered protective. Mice given a 2 106 -challenge were not protected by
LaAg. The association of LaAg with MPLA/AddaVax® was able to enhance the cutaneous hypersensitivity
response compared with LaAg alone. Despite this, there was no difference in proliferative cell
response to antigen ex vivo. Moreover, regardless of the parasite challenge, association of LaAg with
MPL/AddaVax® did not significantly enhance protection in comparison with LaAg alone. This work
demonstrated that MPL/AddaVax® is not effective in improving the efficacy of i.m. LaAg vaccine
against cutaneous leishmaniasis.
Keywords in Portuguese
Leishmania amazonensisVacina LaAg
Adjuvantes
MPLA
AddaVax®
Intramuscular
Imunização
C57BL/6
Keywords
Leishmania amazonensisLaAg vaccine
Adjuvants
MPLA
AddaVax®
Intramuscular
Immunization
C57BL/6
Share